Unraveling the Relationship Between Itching, Scratch Scales, and Biomarkers in Children With Alagille Syndrome

Binita M. Kamath, Cathie Spino, Richard McLain, John C. Magee, Emily M. Fredericks, Kenneth D. Setchell, Alexander Miethke, Jean P. Molleston, Cara L. Mack, Robert H. Squires, Estella M. Alonso, Karen F. Murray, Kathleen M. Loomes, M. Kyle Jensen, Saul J. Karpen, Philip Rosenthal, Danny Thomas, Ronald J. Sokol, Benjamin L. Shneider, for the Childhood Liver Disease Research Network (ChiLDReN) – 26 May 2020 – Pruritus is a debilitating symptom for patients with Alagille syndrome (ALGS).

Microsteatosis in Livers From Donation After Circulatory Death Donors Is Associated With Inferior Outcomes Following Liver Transplantation

Natalie M. Bath, Glen Leverson, David P. Al‐Adra, Anthony M. D’Alessandro, Joshua D. Mezrich, David P. Foley – 26 May 2020 – The acceptable threshold remains unknown for the percentage of macrosteatosis (MaS) and microsteatosis (MiS) to yield optimal outcomes after donation after circulatory death (DCD) liver transplantation (LT). The purpose of this analysis was to determine the impact of donor liver MaS and MiS on DCD LT outcomes.

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score

Stuart C. Gordon, Nandita Kachru, Emily Parker, Stephanie Korrer, A. Burak Ozbay, Robert J. Wong – 26 May 2020 – Limited evidence exists on the clinical and economic burden of advanced fibrosis in patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) due to the invasiveness of liver biopsies for accurately staging liver disease. The fibrosis‐4 (FIB‐4) score allows for noninvasive assessment of liver fibrosis by using clinical and laboratory data alone.

YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte‐Like Cells

Jordan L. Smith, Tomás C. Rodríguez, Haiwei Mou, Suet‐Yan Kwan, Henry Pratt, Xiao‐Ou Zhang, Yueying Cao, Shunqing Liang, Deniz M. Ozata, Tianxiong Yu, Qiangzong Yin, Max Hazeltine, Zhiping Weng, Erik J. Sontheimer, Wen Xue – 26 May 2020

HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination

Benjamin Maasoumy, Anna Maria Geretti, André Frontzek, Harrison Austin, Gudrun Aretzweiler, Monica Garcia‐Álvarez, Susanne Leuchter, Christian O. Simon, Ed G. Marins, Jesse A. Canchola, Markus Cornberg, Rafael Delgado, Heiner Wedemeyer – 26 May 2020 – Despite effective hepatitis B virus (HBV)‐DNA suppression, HBV RNA can circulate in patients receiving nucleoside/nucleotide analogues (NAs).

N‐Terminal PreS1 Sequence Regulates Efficient Infection of Cell‐Culture–Generated Hepatitis B Virus

Asako Murayama, Norie Yamada, Yoshiki Osaki, Masaaki Shiina, Hussein Hassan Aly, Masashi Iwamoto, Senko Tsukuda, Koichi Watashi, Mami Matsuda, Ryosuke Suzuki, Tomohisa Tanaka, Kohji Moriishi, Tetsuro Suzuki, Hironori Nishitsuji, Masaya Sugiyama, Masashi Mizokami, Kunitada Shimotohno, Takaji Wakita, Masamichi Muramatsu, T. Jake Liang, Takanobu Kato – 23 May 2020

Drug‐Induced Liver Injury After Liver Transplantation

Miguel Jiménez‐Pérez, Rocío González‐Grande, Miren García‐Cortés, Raúl J. Andrade – 23 May 2020 – Drug‐induced liver injury (DILI) is an adverse reaction to many drugs in common use that in a liver transplantation (LT) recipient may cause graft dysfunction and may even lead to graft loss and the need for retransplantation. However, several potential clinical scenarios, such as graft rejection and infection, can confound the diagnosis of suspected DILI in the setting of LT.

Subscribe to